Trialjectory, an AI-powered decision-support platform for patients, health-care providers and pharma, raised $20 million in a Series A round led by New York-based global private equity and venture capital firm Insight Partners, with participation from new investor JAL Ventures and from existing investors Contour Venture Partners, Rho Capital and TIA Ventures.
Trialjectory empowers cancer patients to own their treatment journey by creating a personalized treatment plan that enhances physician point of care. Read more.
